Suven Life Sciences Limited has informed the Exchange regarding Outcome of Board Meeting held on May 13, 2025.
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Suven Life Sciences approved audited standalone and consolidated financial results for Q4 and FY25, which show a widened standalone net loss of ₹47.08 crore (vs ₹8.01 crore loss in FY24), driven by a sharp drop in revenue from operations to ₹6.66 crore (vs ₹11.69 crore) and higher R&D spend of ₹30.43 crore. Consolidated net loss stood at ₹160.75 crore (vs ₹105.08 crore). The Board approved a preferential issue of up to 6.4 crore convertible warrants at ₹134 per warrant, raising up to ₹857.64 crore from the promoter group entity and 22 non-promoter investors including Quant Mutual Fund. It also approved increasing the authorised share capital from ₹30 crore to ₹50 crore and the re-appointment of Sudharani Jasti as Whole-time Director for 5 years from November 1, 2025. An EGM is scheduled for June 5, 2025 to seek shareholder approval, and the 36th AGM on August 22, 2025.
Heavy losses are deepening with revenue declining and costs rising, which is negative for shareholders. However, the proposed ₹857.64 crore preferential warrant issue is a large capital infusion that could fund operations and R&D, but it will also dilute existing shareholders once converted. Shareholders will vote on these proposals at the June 5 EGM.